Lifeward Ltd is a medical device company that designs, develops, and commercializes life-changing solutions spanning the continuum of care in physical rehabilitation and recovery, delivering functional and health benefits in clinical settings as well as in the home and community. Its product offerings include the ReWalk Personal Exoskeleton, ReStore Exo-Suit, MYOLYN FES Cycling, and AlterG Anti-Gravity Systems. The company operates in the United States, which generates the majority of its revenue, as well as in Europe, Germany, Asia Pacific, and the rest of the world.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$3.15 – $4.47
Volume26,999
Market cap$10M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$10.28M
Price / earnings
—
Price / book
0.84×
Price / sales
0.47×
EV / sales
0.43×
EV / EBITDA
-0.42×
Profitability
Earnings per share
-$10.86
Return on assets
-88.09%
Return on equity
-252.37%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.7×
Current ratio
2.33×
Quick ratio
1.77×
Cash ratio
0.85×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$17.1M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for LFWD, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$6.62M
$3.92M
$5.08M
$6.2M
$5.72M
$5.03M
$7.55M
$6.13M
Cost of revenue
$3.91M
$2.58M
$3.99M
$3.49M
$3.21M
$2.91M
$5.7M
$3.91M
Gross profit
$2.71M
$1.34M
$1.09M
$2.71M
$2.51M
$2.12M
$1.84M
$2.22M
Selling, general and administrative
$5.11M
$5.84M
$5.36M
$5.13M
$5.52M
$6.06M
$6.15M
$4.4M
Research and development
$1.75M
$5.85M
$843K
$721K
$767K
$918K
$1.13M
$998K
Total operating expenses
$6.86M
$11.68M
$6.21M
$5.85M
$9.07M
$6.98M
$17.07M
$5.39M
Operating income
-$4.15M
-$10.34M
-$5.12M
-$3.14M
-$6.56M
-$4.85M
-$15.23M
-$3.17M
Interest expense
-$352K
-$448K
-$303K
-$23K
$0
$30K
-$47K
$119K
Income before taxes
-$11.51M
-$10.79M
-$5.42M
-$3.16M
-$6.56M
-$4.82M
-$15.28M
-$3.06M
Income taxes
$10K
$6K
-$73K
$7K
$0
$11K
$3K
$29K
Net income
-$11.52M
-$10.79M
-$5.35M
-$3.17M
-$6.56M
-$4.83M
-$15.28M
-$3.08M
Net income attributable to common shareholders
-$11.52M
-$10.79M
-$5.35M
-$3.17M
-$6.56M
-$4.83M
-$15.28M
-$3.08M
EBITDA
-$8.94M
-$5.33M
-$5.05M
-$3.06M
-$3.69M
-$4.76M
-$4.47M
-$2.21M
Basic earnings per share
-$4.12
-$6.70
-$3.57
-$2.40
-$7.01
-$5.53
-$20.81
-$4.20
Diluted earnings per share
-$4.12
-$6.70
-$3.57
-$2.40
-$7.01
-$5.53
-$20.81
-$4.20
Recent news
Company coverage with links to the original publishers.
The global walk assist robot market is projected to grow at a CAGR of 15.01% from 2024 to 2031, driven by AI/ML integration, hybrid wearable systems, rising stroke incidence, and an aging population. Key applications include neuro-rehabilitation, post-surgical rehabilitation, and elderly mobility assistance. North America leads with 39% market share, while Asia-Pacific shows sustained growth potential. High costs and regulatory challenges remain market restraints.
Lifeward (LFWD), a maker of wearable robotic exoskeletons, reported a quarterly loss of $1.32 per share, significantly worse than the consensus estimate of $0.53 loss. The company also missed revenue expectations by 35.92%, posting $5.43 million versus the estimated $8.68 million. The stock has declined 17.4% year-to-date and received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.
BioStem Technologies reported a Q3 loss of $0.53 per share, missing EPS expectations by 23.26%, though it beat revenue estimates with $7.64 million. The company has underperformed the market significantly, down 61.4% year-to-date. With a Zacks Rank #3 (Hold) rating and mixed estimate revisions, the stock is expected to perform in line with the market.
Surgery Partners (SGRY) reported Q3 2026 earnings of $0.16 per share, beating consensus estimates of $0.07 by 128.57%, though revenues slightly missed expectations at $815.3 million. Despite strong year-to-date performance of 50.2%, the company received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends, suggesting near-term underperformance relative to the market.
PACS Group, Inc. reported Q3 2026 earnings of $0.63 per share, beating consensus estimates of $0.56 and showing year-over-year growth from $0.32. Revenue reached $1.5 billion, surpassing estimates by 3.09%. The stock has gained 18.7% year-to-date, outperforming the S&P 500's 10.2% gain. However, the company received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.